Live
- Three persons admitted to hospital for diarrhea treatment
- First Star Outside Milky Way Captured: WOH G64 is 2,000 Times Larger Than the Sun
- Sikkim govt to constitute state Niti Ayog: CM Tamang
- CBI books Rajasthan narcotics inspector for Rs 3 lakh bribe
- Rajasthan bypolls: A tough contest between BJP and Congress
- Albania joins SEPA, paving way for EU integration
- Japanese government approves 250-billion USD economic package to ease price pain
- Six pharma companies to set up their units in Telangana
- The Unstable Events of a 17-Wicket Day in Perth: India vs Australia
- Dutch FM's Israel trip cancelled after Netanyahu's arrest warrant
Hydroxychloroquine is useless: US Study
Hydroxychloroquine, an anti-malarial drug termed potential "game changer" for COVID-19 by US President Donald Trump, showed no benefit in treating patients with the disease in Veterans Health Administration medical centres in the US, says a study.
New York: Hydroxychloroquine, an anti-malarial drug termed potential "game changer" for COVID-19 by US President Donald Trump, showed no benefit in treating patients with the disease in Veterans Health Administration medical centres in the US, says a study.
In fact, the risk of death was found to be higher in those treated with hydroxychloroquine, bought from India, than in the group that included patients not treated with the drug, according to the findings published in the preprint repository medRxiv.
For the study, the researchers performed a retrospective analysis of data from patients hospitalised with confirmed SARSCoV-2 infection in all US Veterans Health Administration medical centres until April 11.
Patients were categorised based on their exposure to hydroxychloroquine alone (HC) or with the antibiotic azithromycin (HC+AZ) as treatments in addition to standard supportive management for Covid-19.
A total of 368 patients were evaluated. Rates of death in the hydroxychloroquine alone group was 27.8 per cent.
The rate of death in the hydroxychloroquine and azithromycin group was 22.1 per cent and in the no hydroxychloroquine, it was even lower, 11.4 per cent, the results showed.
The researchers found that the risk of ventilation was similar in the HC group and in the HC+AZ group, compared to the no HC group.
"In this study, we found no evidence that use of hydroxychloroquine, either with or without azithromycin, reduced the risk of mechanical ventilation in patients hospitalised with Covid-19," said the study carried out by Joseph Magagnoli from Dorn Research Institute, Columbia VA Health Care System and colleagues.
Despite limited and conflicting data on the use of hydroxychloroquine in patients with COVID-19, the US Food and Drug Administration has authorised the emergency use of this drug when clinical trials are unavailable or .
